Company Profile
Biodesix Stock Price, News & Analysis
- Ticker:
- BDSX
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
22.10 USD (-2.99%)
Close
Last updated: August 6, 2026
160M USD
Market cap
Why the stock is moving
Following the latest company update, “Biodesix Announces Second Quarter 2026 Results and Highlights”, BDSX closed down 2.99% at $22.10 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Lung-Disease Diagnostics
Biodesix develops and commercializes diagnostic solutions intended to improve clinical decision-making, with a particular focus on lung disease and oncology. Its tests combine multiple analytical technologies with clinical evidence and laboratory operations.
Diagnostic Testing
The company provides blood-based and other diagnostic tests that help physicians characterize disease, guide treatment and monitor patients. Its commercial laboratory infrastructure supports ordering, sample processing and reporting for routine clinical use.
Development Services
Biodesix also works with biopharmaceutical, life-sciences and research organizations to develop diagnostics, tools and therapeutics. These services combine scientific, technological and operational capabilities and can support biomarker strategy from research through clinical development.
Future catalysts
Biodesix’s catalysts are diagnostic-test adoption, oncology workflow growth, and whether the platform can keep building recurring testing revenue. The market will care about utilization and reimbursement more than a single event.
Recent news
- 01
Biodesix Announces Second Quarter 2026 Results and Highlights
Source: Biodesix
- 02
- 03
- 04
Biodesix to Participate in Upcoming Investor Conferences
Source: Biodesix
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Biodesix (BDSX)?
Biodesix (BDSX) most recently closed at 22.10 USD, a -2.99% move versus the previous session.
What is the market cap of Biodesix (BDSX)?
Biodesix currently has a market capitalization of 160M USD on BioPharmSignal.
What does Biodesix do?
Lung-Disease Diagnostics Biodesix develops and commercializes diagnostic solutions intended to improve clinical decision-making, with a particular focus on lung disease and oncology. Its tests combine multiple analytical technologies with clinical evidence and laboratory operations. Diagnostic Testing The company provides blood-based and other diagnostic...
On which exchange is BDSX stock listed?
Biodesix (BDSX) is associated with NASDAQ, United States, MedTech.
What is Lung-Disease?
Lung-Disease Diagnostics Biodesix develops and commercializes diagnostic solutions intended to improve clinical decision-making, with a particular focus on lung disease and oncology.
Which conditions is Biodesix targeting with Lung-Disease?
Biodesix is associated with oncology based on its company overview and current catalyst commentary.
How does Biodesix describe recent progress with Lung-Disease?
Biodesix’s catalysts are diagnostic-test adoption, oncology workflow growth, and whether the platform can keep building recurring testing revenue. The market will care about utilization and reimbursement more than a single event.
What is Diagnostics?
Lung-Disease Diagnostics Biodesix develops and commercializes diagnostic solutions intended to improve clinical decision-making, with a particular focus on lung disease and oncology.